Literature DB >> 9762376

Isoniazid-induced psychosis.

A O Alao1, J C Yolles.   

Abstract

OBJECTIVE: To report a suspected case of isoniazid-induced psychosis in a 31-year-old woman. CASE
SUMMARY: A 31-year-old white woman without a prior psychiatric history presented with psychotic symptoms suspected to be related to prophylactic treatment with isoniazid after she tested positive to a tuberculin (purified protein derivative) test. The psychotic symptoms resolved partially after isoniazid was discontinued and completely after treatment with olanzapine was begun. The patient remained symptom-free 11 months after discharge from the hospital. DISCUSSION: Cases of isoniazid-related psychiatric disorders reported in the literature include psychosis, obsessive-compulsive neurosis, and mania. With the increasing prevalence of tuberculosis in the US, more people are expected to receive treatment for tuberculosis. Pyridoxine deficiency may play a role in the pathogenesis of isoniazid-induced psychosis. Such deficiency states may be detected indirectly by measuring urinary metabolites of tryptophan.
CONCLUSIONS: Clinicians should be aware of this adverse effect of isoniazid and that it may present with a broad clinical picture.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9762376     DOI: 10.1345/aph.17377

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  11 in total

1.  Cognitive Impairment in Zambians With HIV Infection and Pulmonary Tuberculosis.

Authors:  Knut A Hestad; Jonathan Chinyama; Menon J Anitha; Mary S Ngoma; J Allen McCutchan; Donald R Franklin; Robert K Heaton
Journal:  J Acquir Immune Defic Syndr       Date:  2019-01-01       Impact factor: 3.731

Review 2.  Recent trends on hydrogel based drug delivery systems for infectious diseases.

Authors:  Arti Vashist; Ajeet Kaushik; Atul Vashist; Rahul Dev Jayant; Asahi Tomitaka; Sharif Ahmad; Y K Gupta; Madhavan Nair
Journal:  Biomater Sci       Date:  2016-10-18       Impact factor: 6.843

3.  Medical Co-morbidities Among Patients with Severe Mental Illnesses in a Community Health Facility in Nigeria.

Authors:  Victor Olufolahan Lasebikan; Joachim Azegbeobor
Journal:  Community Ment Health J       Date:  2016-11-25

4.  Neurological and Psychiatric Adverse Effects of Antimicrobials.

Authors:  Madison K Bangert; Rodrigo Hasbun
Journal:  CNS Drugs       Date:  2019-08       Impact factor: 5.749

Review 5.  Nervous system effects of antituberculosis therapy.

Authors:  Joseph S Kass; Wayne X Shandera
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

6.  Isoniazid- and ethambutol-induced psychosis.

Authors:  R Prasad; Rajiv Garg; Sanjay Kumar Verma
Journal:  Ann Thorac Med       Date:  2008-10       Impact factor: 2.219

7.  Crystal structures of human pyridoxal kinase in complex with the neurotoxins, ginkgotoxin and theophylline: insights into pyridoxal kinase inhibition.

Authors:  Amit K Gandhi; Jigar V Desai; Mohini S Ghatge; Martino L di Salvo; Stefano Di Biase; Richmond Danso-Danquah; Faik N Musayev; Roberto Contestabile; Verne Schirch; Martin K Safo
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

8.  Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.

Authors:  Jackson K Mukonzo; Alphonse Okwera; Neoline Nakasujja; Henry Luzze; Deogratious Sebuwufu; Jasper Ogwal-Okeng; Paul Waako; Lars L Gustafsson; Eleni Aklillu
Journal:  BMC Infect Dis       Date:  2013-06-04       Impact factor: 3.090

9.  Psychiatric morbidity and other factors affecting treatment adherence in pulmonary tuberculosis patients.

Authors:  Argiro Pachi; Dionisios Bratis; Georgios Moussas; Athanasios Tselebis
Journal:  Tuberc Res Treat       Date:  2013-04-15

10.  Isoniazid inhibits the heme-based reactivity of Mycobacterium tuberculosis truncated hemoglobin N.

Authors:  Paolo Ascenzi; Andrea Coletta; Yu Cao; Viviana Trezza; Loris Leboffe; Gabriella Fanali; Mauro Fasano; Alessandra Pesce; Chiara Ciaccio; Stefano Marini; Massimo Coletta
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.